BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20150329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20151025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160221
DTEND;VALUE=DATE:20160225
DTSTAMP:20160105T214226Z
CREATED:20151218T174323Z
LAST-MODIFIED:20160105T214226Z
UID:11938-1456012800-1456358399@ces.b2sg.org
SUMMARY:Noncoding RNA in Health and Disease
DESCRIPTION:Meeting Summary\n\nOver the past decade\, there has been a greater understanding of genomic complexity in eukaryotes ushered in by the immense technological advances in high-throughput sequencing of DNA and its corresponding RNA transcripts. This has resulted in the realization that beyond protein-coding genes\, there are a large number of transcripts that do not encode for proteins and\, therefore\, may perform their function through RNA sequences and/or through secondary and tertiary structural determinants. This Keystone Symposia meeting is focused on the latest findings concerning different classes of noncoding RNAs that use different strategies to regulate transcription. These are exciting times for discovering the biological scope and the mechanism of action for these RNA molecules\, which have roles in dosage compensation\, imprinting\, enhancer function and transcriptional regulation\, with a consequently great impact in development and disease.
URL:https://ces.b2sg.org/event/noncoding-rna-in-health-and-disease/
LOCATION:Unnamed Venue\, Santa Fe\, NM\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160217
DTEND;VALUE=DATE:20160218
DTSTAMP:20160111T213040Z
CREATED:20151218T171741Z
LAST-MODIFIED:20160111T213040Z
UID:11927-1455667200-1455753599@ces.b2sg.org
SUMMARY:Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
DESCRIPTION:Purpose: to advance research in cancer etiology and early detection biomarkers\, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate\, Lung\, Colorectal\, and Ovarian Cancer (PLCO) Screening Trial
URL:https://ces.b2sg.org/event/utilizing-the-plco-biospecimens-resource-to-bridge-gaps-in-cancer-etiology-and-early-detection-research-u01-4/
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/NIH2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T210004Z
CREATED:20151218T191013Z
LAST-MODIFIED:20160111T210004Z
UID:11957-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 7: Deliver biologically active macromolecules to and all cells in the body to effectively treat cancer
DESCRIPTION:In recent years\, scientists have been experimenting with using large molecules called ‘macromolecules’ to target and destroy tumour cells. These macromolecules can disrupt the processes that cancer cells use to survive – for example by stopping them from growing or by flagging their presence to the body’s immune system. \nThis approach works very well on cancer cells in the laboratory\, but unlike conventional ‘small molecule’ treatments like aspirin\, it’s really difficult to deliver these molecules to\, and then into\, the cells where they need to act. \nIf we could work out ways of delivering these macromolecules to any and every cell in the body\, it would not only create a totally new way to treat cancer but would have a huge impact on other diseases too.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-7-deliver-biologically-active-macromolecules-to-and-all-cells-in-the-body-to-effectively-treat-cancer/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205935Z
CREATED:20151218T190515Z
LAST-MODIFIED:20160111T205935Z
UID:11956-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 6:  Develop innovative approaches to target the cancer super-controller MYC
DESCRIPTION:Myc is a gene that is mutated and persistently switched on in the majority of human cancers – it’s a hallmark of the disease in nearly seven out of ten cases. \nMutant and overactive Myc helps tumours survive\, and this strongly suggests that blocking its function would be a powerful approach to treating many types of cancer. \nOf course\, Myc isn’t the only gene mutation that’s linked to cancer\, so why is this a Grand Challenge? It’s partly because the gene makes a protein (called MYC) that is a powerful ‘super controller’–a vital hub at the centre of a vast communication network within cells\, and the properties of the MYC protein itself make it really difficult to design a drug against it. \nThat’s why we’re putting out a call to the global research community – this challenge needs more than just money\, it needs new thinking\, innovation and a wide range of expertise.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-6-develop-innovative-approaches-to-target-the-cancer-super-controller-myc/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205820Z
CREATED:20151218T185901Z
LAST-MODIFIED:20160111T205820Z
UID:11955-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 5: Find a way of mapping tumours at the molecular and cellular level
DESCRIPTION:Cancer cells live in complex communities. Just like houses in a city\, each cell in a tumour is different from its neighbour\, and relies on infrastructure to support its existence. \nThere are different neighbourhoods–some worse than others. Where we have roads\, tumours contain blood vessels that deliver nutrients\, and act as highways for different cell types to move around. And when a tumour spreads\, the cancer cells themselves use these blood ‘roads’ to migrate. \nWhat we really need is a Google Earth-like view of a tumour. If we could make a 3D map\, we’d find new targets for treatment and\, eventually\, could use this view to track what’s going on in real time\, such as in response to treatment.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-5-find-a-way-of-mapping-tumours-at-the-molecular-and-cellular-level/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205731Z
CREATED:20151218T184157Z
LAST-MODIFIED:20160111T205731Z
UID:11954-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 4:  Distinguish between lethal cancers that need treating\, and non-lethal cancers that don’t
DESCRIPTION:It’s a hard concept to imagine\, but not all of the things we call ‘cancer’ need to be treated. Some ‘cancers’ are temporary changes to cells that will reverse or disappear with time\, and others are so slow-growing they’ll never cause any problems. \nFor some cancers\, over-diagnosis leads to unnecessary treatment and avoidable side effects. In others\, we desperately need to be able to detect the disease earlier – but do so in a more accurate way. \nIn lung cancer\, for example\, X-ray scans can’t distinguish between spots where there is nothing to worry about\, or the early stages of an aggressive cancer that needs prompt treatment. \nThis is a Grand Challenge that would both save lives and improve quality of life – for millions of people worldwide.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-4-distinguish-between-lethal-cancers-that-need-treating-and-non-lethal-cancers-that-dont/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205641Z
CREATED:20151218T183659Z
LAST-MODIFIED:20160111T205641Z
UID:11953-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 3: Discover how unusual patterns of mutation are induced by different cancer-causing events
DESCRIPTION:Certain things in the world around us\, such as tobacco smoke\, cause cancer. They do this by triggering chemical changes inside cells\, leading to errors in the reading of the DNA genetic code. \nThe patterns of these DNA changes are different for each cause (or ‘carcinogen’) – almost as if they are signing their names on our genomes – and scientists can identify known carcinogens from their chemical signatures. \nBut there are unusual signatures whose origins we don’t know\, caused in ways we haven’t yet identified. And in cancers caused by factors such as obesity\, there will be many different signatures\, and we don’t yet know how to pick them apart. \nSo in the same way that a detective uses forensic evidence from a crime scene to identify a criminal\, we need to work backwards to find these cancer-causing events\, to prevent the cancers they’re causing.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-3-discover-how-unusual-patterns-of-mutation-are-induced-by-different-cancer-causing-events/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205524Z
CREATED:20151218T182244Z
LAST-MODIFIED:20160111T205524Z
UID:11948-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards- Challenge 2: Eradicate EBV-induced cancers from the world
DESCRIPTION:Around 19 in 20 adults carry the Epstein Barr Virus (EBV)\, making it one of the most common human viral infections. \nIn most people\, EBV is relatively harmless\, although it’s the cause of glandular fever\, “kissing disease”. But in some parts of the world it’s a big problem – every year\, EBV infection accounts for 200\,000 new cases of cancer worldwide\, and more than 140\,000 deaths. \nTo eradicate EBV-induced cancers from the world is a grand challenge that would make a significant difference to global health\, and is a fully achievable ambition.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-2-eradicate-ebv-induced-cancers-from-the-world/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160212
DTEND;VALUE=DATE:20160213
DTSTAMP:20160111T205318Z
CREATED:20151218T181421Z
LAST-MODIFIED:20160111T205318Z
UID:11943-1455235200-1455321599@ces.b2sg.org
SUMMARY:Grand Challenge Awards - Challenge 1: Develop vaccines to prevent non-viral cancers
DESCRIPTION:Vaccines already exist that prevent cancers caused by infection\, such as against the human papilloma virus that causes some cervical cancers. But this challenge is to develop vaccines that work against non-viral cancers\, which are caused by faults in our DNA that accumulate over time. \nThat’s what really makes this a Grand Challenge. Because cancer is a disease of the body’s own cells\, it is more challenging to coax the immune system to recognize and eliminate early stage cancers\, where the difference between healthy cells and abnormal cells might be very small. \nBut the promise is huge: imagine if we could vaccinate against cancer as we do for infectious diseases such as TB and measles. Grand Challenge could make this a reality.
URL:https://ces.b2sg.org/event/grand-challenge-awards-challenge-1-develop-vaccines-to-prevent-non-viral-cancers/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160119
DTEND;VALUE=DATE:20160120
DTSTAMP:20160111T205520Z
CREATED:20151218T181151Z
LAST-MODIFIED:20160111T205520Z
UID:11944-1453161600-1453247999@ces.b2sg.org
SUMMARY:Research Travel Award
DESCRIPTION:Cancer Research UK seeks to attract the best postdoctoral researchers to perform groundbreaking cancer research. The purpose of the Research Travel Awards is to enable ambitious postdoctoral researchers to visit research groups elsewhere in the UK or overseas to:\nIntroduce new expertise\, techniques or skills to the travelling scientist’s current research group  Establish or develop collaborations between research groups  Develop their own research career with a view to becoming an independent researcher  Attend a skills-based training course  Pursue a cancer-related project if they do not currently work in cancer research\nResearch Travel Awards are considered by the Research Travel Award Panel.
URL:https://ces.b2sg.org/event/research-travel-award/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160110
DTEND;VALUE=DATE:20160115
DTSTAMP:20160105T213716Z
CREATED:20151218T173720Z
LAST-MODIFIED:20160105T213716Z
UID:11934-1452384000-1452815999@ces.b2sg.org
SUMMARY:Metabolism\, Transcription and Disease
DESCRIPTION:Meeting Summary\n\nTo maintain homeostasis\, cells need to coordinate gene expression and metabolic state. There is increasing evidence that misregulation of metabolic flux and gene transcription plays a major role in human diseases\, including obesity\, diabetes and cancer. The aim of this meeting is to explore how metabolic state influences gene expression programs and\, conversely\, how intermediary metabolism is controlled by the transcription machinery and chromatin-modulating enzymes. Particular emphasis will be on the connection between gene transcription and metabolism in homeostatic and diseased state. Emerging evidence emphasizes that chromatin-modifying enzymes depend on substrates\, or co-factors\, that are key components of intermediary metabolism. The cellular concentration of these metabolites fluctuates in response to\, for example\, nutrient availability\, circadian cycles or oncogenic transformation. Thus\, chromatin might be considered a sensor of metabolic state. Moreover\, some metabolic enzymes play surprisingly direct roles in transcription control. Conversely\, transcriptional control of metabolic enzyme expression\, for example by nuclear receptors or the oncogene Myc\, plays a major role in maintaining homeostasis\, circadian rhythm or driving cell growth and proliferation. The aim of this Keystone Symposia meeting is to bring together scientists working on basic aspects of transcription control\, epigenetics\, metabolic disease and cancer. The meeting should serve as a discussion platform to explore the rapidly growing interphase between transcription regulation\, metabolic reprogramming and human disease.
URL:https://ces.b2sg.org/event/keystone-symposia-on-molecular-and-cellular-biology-metabolism-transcription-and-disease/
LOCATION:Unnamed Venue\, Snowbird\, UT\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160109
DTSTAMP:20181103T130437Z
CREATED:20151218T172802Z
LAST-MODIFIED:20181103T130437Z
UID:11928-1452124800-1452297599@ces.b2sg.org
SUMMARY:USCAP 108th Annual Meeting: ASCP & ASIP Joint Meeting
DESCRIPTION:Current and Future Revolution in Pathology Practice: (Focus on) Immuno-oncology and Cancer Epigenetics \nASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice\, science\, and challenges of immuno-oncology and cancer epigenetics intended to inform and education residents\, fellows\, and practicing pathologists.  The course will begin with a practical discussion of IO in current practice (Mamatha Chivukula\, Sutter Health\, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc.\, with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions. This will be followed up by a discussion of cutting-edge science in the IO space (Mike Milone\, UPenn) with emphasis on those technologies and tools that are likely to move into clinical space soon. This same approach to cancer epigenetics (David Williams\, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics.  To finish off\, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (Idriss M. Bennani-Baiti\, President\, Cancer Epigenetics Society\, Vienna\, Austria). This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care. \nCourse Learning Objectives\nUpon completion of this educational activity\, the learner will be able to: \n\nReview the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc. with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions\nIdentify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics\nAssess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care\n\n\nSESSION CHAIRS\n\n\nModerator \nDanny Milner\, MD\, MSc\, ASCP\n\n\n\n\n\nPRESENTATIONS\n\n\n1:30 PM\n1:35 PM\n\n\nIntroduction to the Session and Outline of the Symposium Objectives\n\n\nDanny Milner\, MD\, MSc\nASCP\n\n\n\n\n\n\n\n1:35 PM\n2:10 PM\n\n\n“Immunotherapy” From Bench to Community Practice- Are Pathologists Ready for the #gamechanger?\n\n\nMamatha Chivukula\, MD\, FASCP\nMills-Peninsula Hospital\, Sutter Health Affiliate\n\n\n\n\n\n\n\n2:10 PM\n2:45 PM\n\n\nCutting Edge Science in Immuno-Oncology: Where to next?\n\n\nMichael Milone\, MD\, Phd\nUniversity of Pennsylvania Perelman School of Medicine\n\n\n\n\n\n\n\n2:45 PM\n3:20 PM\n\n\nBreak\n\n\n\n\n\n\n3:20 PM\n3:55 PM\n\n\nFrom DNA Methylation to Chromatin Remodeling\, the Expanding Role of Epigenetic Changes in Cancer Biology\n\n\nDavid Williams\, MD\, PhD\nUniversity of North Carolina at Chapel Hill\n\n\n\n\n\n\n\n3:55 PM\n4:30 PM\n\n\nPractical Epigenetics: How Today’s Cancer Epigenetics Research Will Change the Field of Pathology Tomorrow\n\n\nIdriss Bennani-Baiti\, PhD\nChildren’s Cancer Research Institute Vienna\n\n\n\n\n\n\n\n4:30 PM\n5:00 PM\n\n\nPanel Discussion\n\n\nDanny Milner\, MD\, MSc
URL:https://ces.b2sg.org/event/ascp-asip-joint-meeting/
LOCATION:National Harbor\, Maryland\, Singapore
CATEGORIES:Meetings
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160108
DTSTAMP:20151218T175506Z
CREATED:20151218T174519Z
LAST-MODIFIED:20151218T175506Z
UID:11932-1452124800-1452211199@ces.b2sg.org
SUMMARY:Research Grant Programm
DESCRIPTION:Supports research projects aimed at understanding the causes of breast cancer\, prevention or developing new treatments for metastatic breast cancer
URL:https://ces.b2sg.org/event/research-grant-programm/
CATEGORIES:Grants
END:VEVENT
END:VCALENDAR